Clinical trial NCT03481192: Voluntary Drug Poisoning by Psychoactive Molecules: Identify Cognitive Markers
Official title: Voluntary Drug Poisoning by Psychoactive Molecules: Identify Cognitive Markers Predictive of a Preserved Memory of Care in Psychiatric Emergencies
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Suicide
Drug Poisoning
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2018-03-29
Enrollment: 103
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: To groups of patients :

A group of patients admitted for IMV exclusively using amnesic substances.

A control group admitted for IMV and ingested exclusively non-amnesic

Two visits, the first one for the first evaluation of cognitive functions directly following the psychiatric interview (E1), and the second one at 24h-48h after the psychiatric evaluation (E2)
Primary purpose: OTHER

Brief summary: To identify in patients admitted for Voluntary drug poisoning (IMV) by psychoactive substances, T1 predictors of T2 recall of psychiatric interview and care project.

Detailed description: The methodology will compare the episodic memory results of patients admitted for IMV who have exclusively ingested amnesic substances to a subject control group that has made IMV with non-amnesic substances such as paracetamol. The purpose of this comparison is to ensure that memory problems are not related to the context of the suicidal crisis.

The second step will be able to relate the memory score of the predictor variables. To achieve this, it will perform a multivariate linear regression in each group in order to confirm the results of the pilot study and to be able to regress in the control group which was not possible in the pilot study because of the lack of effective.

Finally, this study will try to establish, using Receiver Operating Characteristic (ROC) curves, thresholds for cognitive scores and begin to develop a tool for clinical practice.

Eligibility criteria: Inclusion Criteria:

Group amnesic substances :

* Age from 18 to 65 years
* Admitted to emergencies for IMV by benzodiazepines
* Supported at Toulouse University Hospital (hospitalization, outpatient)

Group control :

* Age from 18 to 65 years
* Admitted to emergencies for IMV by non-depressive substances of the central nervous system
* Supported at Toulouse University Hospital (hospitalization, outpatient)

Exclusion Criteria:

* Cognitive Disorder Due to an Organic Disorder Neuro Degenerative Disease, Korsakoff Syndrome) or Mental Retardation Diagnosed
* Patient under guardianship
* Not speaking and / or not reading French
* Neurodegenerative disease diagnosed

Primary outcomes:
measure: Evaluation of the episodic score recall of the first interview (T1) at T2
timeFrame: Just After/24-48h after the psychiatric interview
Secondary outcomes:
measure: Comparison of cognitive scores between the amnesic substances group and the control group using the The Memory Functioning Questionnaire (MFQ) abridged version of tthe Memory Functioning Questionnaire
timeFrame: Just After/24-48h after the psychiatric interview
measure: Sensitivity score of each test for the episodic memory test
timeFrame: Just After/24-48h after the psychiatric interview
measure: Specificity score of each test for the episodic memory test
timeFrame: Just After/24-48h after the psychiatric interview
Other outcomes:
Locations:
city: Toulouse
country: France
facility: University Hospital Toulouse
Study officials:
affiliation: University Hospital, Toulouse
name: Juliette SALLES, MD
role: PRINCIPAL_INVESTIGATOR
References: